elranatamab
pfizer
['magnetismm-1', 'elranatamab', '3192']
bispecific elranatamab induces durable responses in rrmm with overall response rate of 64%, low rate of neurotoxicity (icans), median pfs in these 55 patients in magnetismm-1 was 11.8 months. #ash2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.